CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

BACKGROUND: Osimertinib is an oral, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor activating mutation (EGFRm) and the resistance mutation (T790M) that is FDA approved for patients with EGFR mutant lung cancer. The synergism between Osimertinib and rad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Rauf, Yasmeen, Kotecha, Rupesh, Fadul, Camilo, Evanoff, Wendi, Suh, John, Chao, Samuel, Murphy, Erin, Yu, Jennifer, Angelov, Lilyana, Barnett, Gene, Mohammadi, Alireza, Ahluwalia, Manmeet
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651084/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados